The Duke Cancer Network has expertise in building value-based programs that define best practices and enhance quality to best serve the needs of your community.
In BRAF MT #colorectalcancer treated with vemurafenib/iri/cetux, selective pressure might cause progression due to deactivation of MAPK pathway #DukeGIDebates
Promising preliminary data from BEACON ( encorafenib + binimetinib + cetuximab) by @skopetz suggests possible new regimen for #colorectalcancer patients with BRAF MT #DukeGIDebates